Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan

[1]  P. Munroe,et al.  Over 1,000 genetic loci influencing blood pressure with multiple systems and tissues implicated. , 2019, Human molecular genetics.

[2]  Y. Bossé,et al.  Benefits and limitations of genome-wide association studies , 2019, Nature Reviews Genetics.

[3]  O. Alfieri,et al.  Lanosterol Synthase Genetic Variants, Endogenous Ouabain, and Both Acute and Chronic Kidney Injury. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  C. Drummond,et al.  Na/K-ATPase signaling mediates miR-29b-3p regulation and cardiac fibrosis formation in mice with chronic kidney disease , 2018, PloS one.

[5]  S. Textor,et al.  Current Concepts in the Treatment of Renovascular Hypertension. , 2018, American journal of hypertension.

[6]  M. Munafo,et al.  Robust research needs many lines of evidence , 2018, Nature.

[7]  W. Young,et al.  Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. , 2017, The lancet. Diabetes & endocrinology.

[8]  M. Blaustein.  How does pressure overload cause cardiac hypertrophy and dysfunction? High-ouabain affinity cardiac Na+ pumps are crucial. , 2017, American journal of physiology. Heart and circulatory physiology.

[9]  J. Tian,et al.  Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target. , 2017, Cardiovascular pharmacology: open access.

[10]  W. Rief,et al.  Effect of placebo groups on blood pressure in hypertension: a meta-analysis of beta-blocker trials. , 2016, Journal of the American Society of Hypertension : JASH.

[11]  F. Montorsi,et al.  Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury , 2016, International journal of molecular sciences.

[12]  Steven N. Goodman,et al.  Aligning statistical and scientific reasoning , 2016, Science.

[13]  J. Staessen,et al.  Personalized Therapy of Hypertension: the Past and the Future , 2016, Current Hypertension Reports.

[14]  Mingyu Liang,et al.  Ushering Hypertension Into a New Era of Precision Medicine. , 2016, JAMA.

[15]  P. Munroe,et al.  Genome-wide association studies and contribution to cardiovascular physiology. , 2015, Physiological genomics.

[16]  M. Rastaldi,et al.  Rostafuroxin Protects from Podocyte Injury and Proteinuria Induced by Adducin Genetic Variants and Ouabain , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[17]  Chris S. Haley,et al.  Detecting epistasis in human complex traits , 2014, Nature Reviews Genetics.

[18]  H. Takagi,et al.  A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction , 2014, Hypertension Research.

[19]  P. Ferrari.  Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. , 2010, Biochimica et biophysica acta.

[20]  L. Citterio,et al.  Genetics of primary hypertension: the clinical impact of adducin polymorphisms. , 2010, Biochimica et biophysica acta.

[21]  M. Rastaldi,et al.  Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 1: Experimental Studies , 2010, Science Translational Medicine.

[22]  Erika Salvi,et al.  Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 2: Clinical Studies , 2010, Science Translational Medicine.

[23]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[24]  W. Elliott.  Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .

[25]  D. Wald,et al.  Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .

[26]  C. Zurzolo,et al.  alpha-Adducin mutations increase Na/K pump activity in renal cells by affecting constitutive endocytosis: implications for tubular Na reabsorption. , 2008, American journal of physiology. Renal physiology.

[27]  M. Burnier,et al.  Relationships among endogenous ouabain, α-adducin polymorphisms and renal sodium handling in primary hypertension , 2008, Journal of hypertension.

[28]  G. Bianchi,et al.  Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[29]  G. Bianchi.  Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  J. Zwiller,et al.  Hypertension-Linked Mutation in the Adducin &agr;-Subunit Leads to Higher AP2-&mgr;2 Phosphorylation and Impaired Na+,K+-ATPase Trafficking in Response to GPCR Signals and Intracellular Sodium , 2004, Circulation research.

[31]  G. Bianchi,et al.  Organ Hypertrophic Signaling within Caveolae Membrane Subdomains Triggered by Ouabain and Antagonized by PST 2238* , 2004, Journal of Biological Chemistry.

[32]  P. Manunta,et al.  Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. , 1997, Hypertension.

[33]  Cristina Barlassina,et al.  Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension , 1997, The Lancet.

[34]  L Zagato,et al.  Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. , 1997, Lancet.

[35]  F. Valtorta,et al.  Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. , 1996, The Journal of clinical investigation.

[36]  P. Manunta,et al.  Ouabain‐induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure , 1994, Journal of hypertension.

[37]  D. Cusi,et al.  Two point mutations within the adducin genes are involved in blood pressure variation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Brown,et al.  Comparison of Surgery and Prolonged Spironolactone Therapy in Patients with Hypertension, Aldosterone Excess, and Low Plasma Renin , 1972, British medical journal.